Apogem Capital’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
– Sell
-28,584
Closed -$1.22M – 41
2022
Q3
$1.22M Buy
28,584
+883
+3% +$45.2K 1.21% 17
2022
Q2
$1.55M Buy
27,701
+98
+0.4% +$5.81K 1.4% 13
2022
Q1
$1.71M Buy
27,603
+1,625
+6% +$99.5K 1.17% 13
2021
Q4
$1.43M Buy
25,978
+6,711
+35% +$350K 0.94% 25
2021
Q3
$1.01M Buy
19,267
+13,734
+248% +$815K 0.65% 47
2021
Q2
$381K Buy
5,533
+422
+8% +$32.2K 0.24% 130
2021
Q1
$394K Buy
+5,111
New +$471K 0.27% 123

Other funds holding LKFT

Apogem Capital's LKFT Position: Q4 2022 in Review

Apogem Capital sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2022, closing a stake of 28,584 shares — an estimated $1.22M sold.

Apogem Capital first reported a position in LKFT in Q1 2021 and held it in 7 quarters. The position peaked at $1.71M in Q1 2022. 74 funds tracked by Wall St. Rank hold LKFT as of Q4 2022.

  • Apogem Capital reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2022 after selling out during the quarter.
  • Apogem Capital sold 28,584 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2022, an estimated $1.22M.
  • Apogem Capital first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2021 and held it in 7 quarters.
  • Apogem Capital's Lakefront Biotherapeutics American Depositary Shares position peaked at $1.71M in Q1 2022.
  • 74 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2022.

Based on Apogem Capital's 13F filing for Q4 2022, filed 13 Feb 2023.